These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study. Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896 [TBL] [Abstract][Full Text] [Related]
9. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial. Yu S; Guo A; Wang Z; Liu J; Tan G; Yang Q; Zhang M; Yibulaiyin H; Chen H; Zhang Y; Croop R; Sun Y; Liu Y; Zhao Q; Lu Z J Headache Pain; 2024 Apr; 25(1):57. PubMed ID: 38627638 [TBL] [Abstract][Full Text] [Related]
10. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501 [TBL] [Abstract][Full Text] [Related]
11. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment. Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110 [TBL] [Abstract][Full Text] [Related]
12. Variation in Endpoints in FDA Medication Approvals: A Review of Acute and Preventive Migraine Medications. Sharpless LK; Kesselheim AS; Orr SL; Darrow J Neurology; 2023 Sep; 101(10):e989-e1000. PubMed ID: 37438124 [TBL] [Abstract][Full Text] [Related]
13. Results of a Web-Based Survey on 2105 Greek Migraine Patients-Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients' Reported Satisfaction. Dermitzakis EV; Kouroudi A; Argyriou AA; Spingos KC; Bilias K; Vikelis M Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676655 [No Abstract] [Full Text] [Related]
14. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks. Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275 [TBL] [Abstract][Full Text] [Related]
15. Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study. Seo J; Smith CA; Thomas C; Tervonen T; Hareendran A; Ford JH; Stauffer VL; Nicholson RA; Duffy KH; Tockhorn-Heidenreich A Patient; 2022 Jan; 15(1):93-108. PubMed ID: 34131880 [TBL] [Abstract][Full Text] [Related]
16. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924 [TBL] [Abstract][Full Text] [Related]
17. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168 [TBL] [Abstract][Full Text] [Related]
18. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. MacGregor EA; Brandes J; Eikermann A Headache; 2003 Jan; 43(1):19-26. PubMed ID: 12864754 [TBL] [Abstract][Full Text] [Related]
19. Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options. Dermitzakis EV; Argyriou AA; Bilias K; Barmpa E; Liapi S; Rikos D; Xiromerisiou G; Soldatos P; Vikelis M J Clin Med; 2024 May; 13(10):. PubMed ID: 38792309 [No Abstract] [Full Text] [Related]
20. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Hubig LT; Smith T; Chua GN; Lloyd AJ; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lo SH Headache; 2022 Oct; 62(9):1187-1197. PubMed ID: 36047857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]